Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SENP5 | Q96HI0 | 3/20 | 0.42 |
| ▸ | SENP2 | Q9HC62 | 3/20 | 0.42 |
| ▸ | SENP1 | Q9P0U3 | 3/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742814 | 0.89 | MEN1 (0.42) | EDNRAMEN1KMT2APDE10ASTING1 | |
| SCHEMBL9371330 | 0.89 | EDNRA (0.56) | EDNRAMRGPRX4KDM4EALDH1A1SENP5 | |
| SCHEMBL5215575 | 0.87 | EDNRA (0.49) | EDNRAKDM4EALDH1A1SENP5SENP2 | |
| SCHEMBL5212069 | 0.85 | EDNRA (0.48) | EDNRAMRGPRX4KDM4EALDH1A1SENP5 | |
| SCHEMBL5217459 | 0.84 | STING1 (0.46) | EDNRAMEN1KMT2AMRGPRX4KDM4E | |
| SCHEMBL4634005 | 0.84 | SENP5 (0.56) | EDNRAMRGPRX4KDM4EALDH1A1SENP5 | |
| SCHEMBL5213824 | 0.83 | STING1 (0.44) | EDNRAMRGPRX4KDM4EALDH1A1SENP5 | |
| SCHEMBL5211216 | 0.83 | PARP15 (0.47) | EDNRAMRGPRX4KDM4EALDH1A1SENP5 | |
| SCHEMBL5217366 | 0.83 | PARP15 (0.49) | MEN1KMT2AKDM4EALDH1A1SENP5 | |
| SCHEMBL5215223 | 0.82 | RXRB (0.46) | EDNRAMEN1KMT2AMRGPRX4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636213-B1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | WARNER LAMBERT CO (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1636213-A1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | BRUENDL MICHELLE M (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108715-A1 | 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259926-A1 | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents | MALT1, CYP1B1, CYP4B1 | EDNRA 1664/4885MEN1 4169/4885KMT2A 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.